ANRIL
rnaANRIL lncRNA at the 9p21.3 CAD locus regulates epigenetic pathways driving atherosclerotic inflammation and vascular disease.
Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
Rationale9p21.3 CAD risk locus; epigenetic regulation of atherosclerosis.
Also acts inLipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I35
C — confounder / Type-II48
A — assay feasibility50
E — evidence strength19
T1DI (composite)4
Specificity differential (R−C)-13
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood (transcript)
Collection tube
PAXgene/Tempus RNA tube · K2/K3-EDTA (lavender-top)
Method / principle
RT-qPCR (TaqMan) or small-RNA sequencing
Reagent / substrate
Target-specific primers/probe; reverse transcriptase (miRNA: stem-loop RT primer)
Platform
qPCR instrument / NGS
Turnaround · availability
Research / send-out · Research (few LDTs)
Literature evidence(4)
- Association between lncRNA ANRIL genetic variants with the susceptibility to ischemic stroke: From a case-control study to meta-analysis.Medicine · 2021 · PMID 33725991 · doi
- Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs?Trends in endocrinology and metabolism: TEM · 2015 · PMID 25744911 · doi
- From genotype to phenotype in human atherosclerosis--recent findings.Current opinion in lipidology · 2013 · PMID 24005217 · doi
- Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke.BMC medicine · 2012 · PMID 22776031 · doi